Please enter exact key words
Antibody Therapeutics Targeting GLP-1R

for the Treatment of Hypoglycemia or Diabetes

Home / Available Projects / Antibody Therapeutics Targeting GLP-1R

Antibody Therapeutics Targeting GLP-1R

Drug Name GPCR-targeted Project 012

Glucagon-like peptide-1 receptor (GLP-1R) is a class B G-protein-coupled receptor (GPCR) that acts as the receptor for the incretin GLP-1, a peptide released to regulate insulin levels in response to food intake. High-affinity antibodies targeting GLP-1R are being developed for multiple indications such as type II diabetes and hypoglycemia. These antibodies are screened, humanized, and engineered through a proprietary GPCR monoclonal antibody development platform and showed either GLP-1R agonistic or antagonistic properties in early studies.

Target Glucagon-like peptide-1 receptor (GLP-1R)
Drug Modality Monoclonal antibody
Indication Hypoglycemia; Type 2 diabetes mellitus
Product Category Biologic
Mechanism of Action GLP-1R agonists; GLP-1R antagonists
Status Preclinical
Patent Granted

More Detail Available Upon Request

We look forward to hearing from you.

Our customer service representatives are available 24 hours a day, from Monday to Sunday Online Inquiry

Protheragen's business is growing rapidly after founded in Ronkonkoma, New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.

Protheragen Inc.